A new online pharmacy service is offering U.S. patients with non-small cell lung cancer (NSCLC) a potential lifeline by providing access to Tagrisso at dramatically reduced prices. SaveRxCanada.to has partnered with licensed Indian suppliers to offer the AstraZeneca medication at a fraction of U.S. market costs.
Tagrisso, a targeted therapy for NSCLC patients with specific EGFR mutations, typically costs between $15,000 to $18,000 per month in the United States. Through the international pharmacy service, patients can now obtain the same medication for approximately $12,500 monthly, representing potential savings of up to $5,500 per month.
The medication is particularly important for patients with EGFR-mutant lung cancer, offering treatment options for both initial diagnosis and cases where cancer has progressed after previous therapies. It targets specific genetic mutations, including the challenging T790M resistance mutation, and has become a standard treatment for many lung cancer patients.
While the medication offers significant financial relief, patients are advised to consult their oncologists about potential side effects, which can include diarrhea, rash, skin and nail changes, fatigue, and decreased appetite. Rare but serious complications may also occur, necessitating close medical supervision.
The service requires a valid prescription and ensures product authenticity through certified international suppliers, providing prescription validation, secure shipping, and appropriate medication handling. This approach offers a potential solution for patients struggling with the high cost of critical cancer treatments in the United States.
